{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:11:32Z","timestamp":1759230692268,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Non-alcoholic steatohepatitis (NASH) is a progressive liver disease with lipid accumulation, inflammation, and liver fibrosis. Ponatinib, a third-generation tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, was found to improve metabolic disorders in mice. However, the role of ponatinib in liver inflammation and fibrosis remains to be elucidated. Here we aimed to determine the effect of ponatinib in non-alcoholic steatohepatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We explored the function and mechanism of ponatinib using a mouse model of NASH induced by a methionine and choline deficient (MCD) diet and LO2 cells cultured in MCD mimic medium.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Here, we found that ponatinib reduced liver lipid deposition, fibrosis, and inflammation induced by MCD diet without affecting body weight and blood glucose. Meanwhile, we found that ponatinib attenuated steatohepatitis and inflammation in LO2 cells induced by MCD mimic medium. We further discovered that the expression levels of LC3II and lysosomal associated membrane protein 1 (LAMP1) were reduced and the expression level of p62 was upregulated in both mouse and cell models, suggesting that autophagy was inhibited, which was restored by ponatinib treatment. In addition, transcription factor EB (TFEB) is a major regulator of autophagy and lysosome biogenesis and the transcription and protein expression levels of TFEB were decreased in steatosis hepatocytes, which could be ameliorated by ponatinib treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results revealed that the beneficial effects of ponatinib on NASH via TFEB-mediated autophagy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1505768","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:08:52Z","timestamp":1736233732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhuomiao","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xihui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guozhu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.podrm.2023.11.005","article-title":"Ponatinib: a comprehensive drug profile","volume":"49","author":"Attwa","year":"2024","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.apsb.2021.07.021","article-title":"Therapeutic regulation of autophagy in hepatic metabolism","volume":"12","author":"Byrnes","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B5","doi-asserted-by":"publisher","first-page":"eaau0731","DOI":"10.1126\/sciadv.aau0731","article-title":"Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations","volume":"4","author":"Choi","year":"2018","journal-title":"Sci. Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41401-021-00768-4","article-title":"Roflupram protects against rotenone-induced neurotoxicity and facilitates \u03b1-synuclein degradation in Parkinson's disease models","volume":"42","author":"Dong","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"B7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41423-018-0032-0","article-title":"Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice","volume":"16","author":"Du","year":"2019","journal-title":"Cell Mol. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","article-title":"The menage a trois of autophagy, lipid droplets and liver disease","volume":"18","author":"Filali-Mouncef","year":"2022","journal-title":"Autophagy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M22-1787","article-title":"Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial","volume":"176","author":"Hansen","year":"2023","journal-title":"Ann. Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2016.02.017","article-title":"Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2\/vasohibin-1","volume":"148","author":"Kang","year":"2016","journal-title":"Life Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.gene.2017.09.036","article-title":"Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia","volume":"637","author":"Kayabasi","year":"2017","journal-title":"Gene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1040999","DOI":"10.3389\/fphar.2022.1040999","article-title":"Ponatinib modulates the metabolic profile of obese mice by inhibiting adipose tissue macrophage inflammation","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"176215","DOI":"10.1016\/j.ejphar.2023.176215","article-title":"OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes","volume":"962","author":"Melander","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1016\/s0021-9258(18)67021-8","article-title":"Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P","volume":"261","author":"Payan","year":"1986","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"20420188221145549","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front. Cardiovasc Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.mam.2021.100973","article-title":"Autophagy in liver diseases: a review","volume":"82","author":"Qian","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pupt.2015.07.004","article-title":"Ponatinib ameliorates pulmonary fibrosis by suppressing TGF-\u03b21\/Smad3 pathway","volume":"34","author":"Qu","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/15548627.2023.2254191","article-title":"Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease","volume":"20","author":"Ren","year":"2024","journal-title":"Autophagy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2003.09.020","article-title":"The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance","volume":"40","author":"Rinella","year":"2004","journal-title":"J. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41419-023-05853-6","article-title":"Butyrate limits inflammatory macrophage niche in NASH","volume":"14","author":"Sarkar","year":"2023","journal-title":"Cell Death Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on NAFLD: focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nature07976","article-title":"Autophagy regulates lipid metabolism","volume":"458","author":"Singh","year":"2009","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trsl.2020.07.008","article-title":"The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet","volume":"227","author":"Somm","year":"2021","journal-title":"Transl. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"101806","DOI":"10.1016\/j.molmet.2023.101806","article-title":"Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy","volume":"78","author":"Song","year":"2023","journal-title":"Mol. Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1097\/QAD.0b013e32835804f9","article-title":"Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation","volume":"26","author":"Stankov","year":"2012","journal-title":"AIDS"},{"key":"B30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","article-title":"New insights into activation and function of the AMPK","volume":"24","author":"Steinberg","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e57574","DOI":"10.15252\/embr.202357574","article-title":"The post-translational regulation of transcription factor EB (TFEB) in health and disease","volume":"24","author":"Takla","year":"2023","journal-title":"EMBO Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance","volume":"44","author":"Von Eckardstein","year":"2023","journal-title":"Eur. Heart J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e166149","DOI":"10.1172\/JCI166149","article-title":"TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase","volume":"134","author":"Xu","year":"2024","journal-title":"J. Clin. Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"155200","DOI":"10.1016\/j.metabol.2022.155200","article-title":"Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK\/mTOR signaling pathway","volume":"131","author":"Yan","year":"2022","journal-title":"Metabolism"},{"key":"B37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1172\/JCI121842","article-title":"STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis","volume":"129","author":"Yu","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.122.063029","article-title":"Bestrophin3 deficiency in vascular smooth muscle cells activates MEKK2\/3-MAPK signaling to trigger spontaneous aortic dissection","volume":"148","author":"Zhang","year":"2023","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.biopha.2017.07.168","article-title":"Lipophagy and liver disease: new perspectives to better understanding and therapy","volume":"97","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1505768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:08:54Z","timestamp":1736233734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1505768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":39,"alternative-id":["10.3389\/fphar.2024.1505768"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1505768","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1505768"}}